Table: Taisho Pharmaceutical HD - 9-MTH group results
Feb 14 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2019 Dec 31, 2018 Mar 31, 2020
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 211.34 199.90 290.50
(+5.7 pct) (-7.4 pct) (+11.1 pct)
Operating 17.57 28.12 21.50
(-37.5 pct) (-1.5 pct) (-31.1 pct)
Recurring 20.97 36.16 26.00
(-42.0 pct) (+8.3 pct) (-36.4 pct)
Net 17.93 51.40 21.00
(-65.1 pct) (+94.2 pct) (-56.8 pct)
EPS 224.64 yen 643.93 yen 263.13 yen
EPS Diluted 224.38 yen 643.33 yen
Ann Div 120.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 70.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10